Literature DB >> 27001566

Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!

Agnieszka Korfel1, Marc Chamberlain2, Ed Neuwelt3, Eckhard Thiel4, Nancy Doolittle3, Uwe Schlegel5, Martin Dreyling6, James Rubenstein7, Lars Fischer4, Magnus Björkholm8, Peter Martus9, Michael Weller10, Michael Glantz11.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27001566      PMCID： PMC5321044          DOI： 10.1200/JCO.2015.65.0879

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.

Authors:  Agnieszka Korfel; Thomas Elter; Eckhard Thiel; Matthias Hänel; Robert Möhle; Roland Schroers; Marcel Reiser; Martin Dreyling; Jan Eucker; Christian Scholz; Bernd Metzner; Alexander Röth; Josef Birkmann; Uwe Schlegel; Peter Martus; Gerard Illerhaus; Lars Fischer
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

2.  High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

Authors:  Andrés J M Ferreri; Giovanni Donadoni; Maria Giuseppina Cabras; Caterina Patti; Michael Mian; Renato Zambello; Corrado Tarella; Massimo Di Nicola; Alfonso M D'Arco; Gianluca Doa; Marta Bruno-Ventre; Andrea Assanelli; Marco Foppoli; Giovanni Citterio; Alessandro Fanni; Antonino Mulè; Federico Caligaris-Cappio; Fabio Ciceri
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544
  2 in total
  1 in total

1.  MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.

Authors:  Alexander Baraniskin; Monika Chomiak; Guido Ahle; Thomas Gress; Malte Buchholz; Michael Turewicz; Martin Eisenacher; Michelle Margold; Uwe Schlegel; Wolff Schmiegel; Stephan Hahn; Roland Schroers
Journal:  J Neurooncol       Date:  2018-01-11       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.